300 results match your criteria: "Vanderbilt Heart and Vascular Institute[Affiliation]"

Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints.

J Am Coll Cardiol

October 2023

Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Munich, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.

Article Synopsis
  • Interest in the management of tricuspid regurgitation (TR) has increased due to studies showing worse outcomes with greater TR severity, even when considering other health issues.
  • Historically, surgery for TR has had high mortality rates, prompting the creation of transcatheter treatment options.
  • The Tricuspid Valve Academic Research Consortium aims to standardize disease definitions and trial endpoints to improve research and patient outcomes related to TR.
View Article and Find Full Text PDF

Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints.

Ann Thorac Surg

November 2023

Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Munich, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.

Article Synopsis
  • Interest in tricuspid regurgitation (TR) has increased due to studies linking higher TR severity to worse patient outcomes, even considering other health conditions.
  • Due to high in-hospital mortality with traditional surgery for TR, new less invasive transcatheter treatment options have been developed.
  • The first document from the Tricuspid Valve Academic Research Consortium aims to standardize definitions and endpoints for research trials to improve understanding and management of TR, with a follow-up document planned to focus on trial design and further endpoint definitions.
View Article and Find Full Text PDF
Article Synopsis
  • Interest in tricuspid regurgitation (TR) has increased due to studies showing worse patient outcomes correlating with higher severity of TR.
  • Surgery for the tricuspid valve has historically had high in-hospital mortality rates, prompting the development of new, less invasive transcatheter treatment options.
  • The first document from the Tricuspid Valve Academic Research Consortium aims to standardize definitions of TR and trial endpoints, which will enhance comparison and understanding in future clinical trials.
View Article and Find Full Text PDF

Cardio-Obstetrics and Heart Failure: JACC: Heart Failure State-of-the-Art Review.

JACC Heart Fail

September 2023

Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address:

Heart failure and cardiomyopathy are significant contributors to pregnancy-related deaths, as maternal morbidity and mortality have been increasing over time. In this setting, the role of the multidisciplinary cardio-obstetrics team is crucial to optimizing maternal, obstetrical and fetal outcomes. Although peripartum cardiomyopathy is the most common cardiomyopathy experienced by pregnant individuals, the hemodynamic changes of pregnancy may unmask a pre-existing cardiomyopathy leading to clinical decompensation.

View Article and Find Full Text PDF

There is growing evidence that severe tricuspid regurgitation (TR) impacts clinical outcomes in a variety of cardiovascular disease states. The late presentation of patients with advanced TR highlights the underappreciation of the disease, as well as the pitfalls of current guideline-directed medical management. Given the high in-hospital mortality associated with isolated tricuspid valve surgery, transcatheter options continue to be explored with the hope of improved survival and reduced heart failure hospitalizations.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with heart failure and secondary mitral regurgitation (SMR) experience worse health outcomes and quality of life compared to those without SMR.
  • Guideline-directed medical therapy remains the primary treatment for SMR, and recent trials on mitral transcatheter edge-to-edge repair have improved insights on which patients might benefit from these procedures with a focus on multidisciplinary care.
  • The success of these repairs has led to investigations into their use in populations like end-stage heart failure and cardiogenic shock, alongside ongoing development of new transcatheter devices to enhance treatment options for patients with symptomatic SMR.
View Article and Find Full Text PDF

Background: Little is known regarding the risk of cerebrovascular events (CVE) in patients with heart failure and severe secondary mitral regurgitation treated with transcatheter edge-to-edge repair (TEER).

Objectives: The study sought to examine the incidence, predictors, timing, and prognostic impact of CVE (stroke or transient ischemic attack) in the COAPT (Cardiovascular Outcomes Assessment of the Mitraclip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial.

Methods: A total of 614 patients with heart failure and severe secondary mitral regurgitation were randomized to TEER plus guideline-directed medical therapy (GDMT) vs GDMT alone.

View Article and Find Full Text PDF
Article Synopsis
  • Malnutrition affects heart failure patients with severe secondary mitral regurgitation, with 17% of the study participants classified as malnourished, leading to a higher 4-year mortality rate.
  • The study analyzed patients who underwent transcatheter edge-to-edge repair (TEER) with MitraClip alongside guideline-directed medical therapy (GDMT) versus GDMT alone.
  • Findings revealed that malnutrition was linked to increased mortality over four years, while TEER significantly lowered both mortality and heart failure hospitalizations, regardless of malnutrition status.
View Article and Find Full Text PDF

Background: In patients with symptomatic heart failure (HF) and previous heart failure hospitalization (HFH), hemodynamic-guided HF management using a wireless pulmonary artery pressure (PAP) sensor reduces HFH, but it is unclear whether these benefits extend to patients who have not been recently hospitalized but remain at risk because of elevated natriuretic peptides (NPs).

Objectives: This study assessed the efficacy and safety of hemodynamic-guided HF management in patients with elevated NPs but no recent HFH.

Methods: In the GUIDE-HF (Hemodynamic-Guided Management of Heart Failure) trial, 1,000 patients with New York Heart Association (NYHA) functional class II to IV HF and either previous HFH or elevated NP levels were randomly assigned to hemodynamic-guided HF management or usual care.

View Article and Find Full Text PDF

Early telemonitoring of weights and symptoms did not decrease heart failure hospitalizations but helped identify steps toward effective monitoring programs. A signal that is accurate and actionable with response kinetics for early re-assessment is required for the treatment of patients at high risk, while signal specifications differ for surveillance of low-risk patients. Tracking of congestion with cardiac filling pressures or lung water content has shown most impact to decrease hospitalizations, while multiparameter scores from implanted rhythm devices have identified patients at increased risk.

View Article and Find Full Text PDF

Transcatheter Tricuspid Interventions: Past, Present, and Future.

Methodist Debakey Cardiovasc J

May 2023

Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center, Nashville, Tennessee, US.

Tricuspid regurgitation (TR) etiologies include primary valve pathology or secondary (functional) regurgitation from increased hemodynamic pressure or volume on the right side of the heart. Patients with severe TR have a worse prognosis independent of all other variables. Surgical treatment for TR has mostly been limited to patients undergoing concomitant left-sided cardiac surgery.

View Article and Find Full Text PDF

Transcatheter Mitral Valve Replacement Versus Medical Therapy for Secondary Mitral Regurgitation: A Propensity Score-Matched Comparison.

Circ Cardiovasc Interv

June 2023

Cardiovascular Research Foundation, New York City, NY (S.L., D.J.C., A.C., A.S., Z.Z., Y.L., B.R., J.F.G.).

Background: Transcatheter mitral valve replacement (TMVR) is an emerging therapeutic alternative for patients with secondary mitral regurgitation (MR). Outcomes of TMVR versus guideline-directed medical therapy (GDMT) have not been investigated for this population. This study aimed to compare clinical outcomes of patients with secondary MR undergoing TMVR versus GDMT alone.

View Article and Find Full Text PDF

Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation.

N Engl J Med

June 2023

From the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), Columbia University Medical Center (S.O.M.), and the Cardiovascular Research Foundation (D.J.C.), New York, and St. Francis Hospital and Heart Center, Roslyn (D.J.C.) - all in New York; the Departments of Medicine, Physiology, and Cell Biology, Division of Cardiovascular Medicine, and the Davis Heart and Lung Research Institute, Ohio State University, Columbus (W.T.A.), the Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland (S.R.K.), and Lindner Clinical Research Center and the Christ Hospital, Cincinnati (I.J.S.); Advanced Heart Failure, Vanderbilt Heart and Vascular Institute, Nashville (J.A.L.); the Division of Cardiology, HCA Healthcare, Los Angeles (S.K.), and Kaiser Permanente-San Francisco Hospital, San Francisco (J.M.M.); Baylor University Medical Center, Baylor Heart and Vascular Institute, Dallas (P.A.G.), and Baylor Scott and White Heart Hospital Plano, Plano (M.J.M.) - both in Texas; the Division of Cardiology, University of Virginia, Charlottesville (D.S.L.); Intermountain Medical Center, Murray, UT (B.W.); Carolinas Medical Center, Charlotte, NC (M.R.); Piedmont Hospital, Atlanta (V.R.); University of Colorado Hospital, Aurora (A.B.); and MedStar Health Research Institute, Hyattsville, MD (F.M.A.).

Background: Data from a 5-year follow-up of outcomes after transcatheter edge-to-edge repair of severe mitral regurgitation, as compared with outcomes after maximal doses of guideline-directed medical therapy alone, in patients with heart failure are now available.

Methods: We randomly assigned patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remained symptomatic despite the use of maximal doses of guideline-directed medical therapy to undergo transcatheter edge-to-edge repair plus receive medical therapy (device group) or to receive medical therapy alone (control group) at 78 sites in the United States and Canada. The primary effectiveness end point was all hospitalizations for heart failure through 2 years of follow-up.

View Article and Find Full Text PDF

Aims: Low serum albumin levels are associated with poor prognosis in numerous chronic disease states but the relationship between albumin and outcomes in patients with heart failure (HF) and secondary mitral regurgitation (SMR) has not been described.

Methods And Results: The randomized COAPT trial evaluated the safety and effectiveness of transcatheter edge-to-edge repair (TEER) with the MitraClip plus guideline-directed medical therapy (GDMT) versus GDMT alone in patients with symptomatic HF and moderate-to-severe or severe SMR. Baseline serum albumin levels were measured at enrolment.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the impact of peripheral artery disease (PAD) on the outcomes of transcatheter mitral valve repair (TMVr) in heart failure (HF) patients with severe mitral regurgitation, comparing results with guideline-directed medical therapy (GDMT) alone.
  • Among 614 patients, 109 had PAD; findings showed that PAD was linked to higher mortality but did not affect hospitalization rates for heart failure.
  • TMVr significantly reduced mortality for patients without PAD, but not for those with PAD; however, it consistently decreased hospitalization rates and improved health status and exercise capacity for all patients regardless of PAD status.
View Article and Find Full Text PDF

Introduction: Inpatient falls within the Epilepsy Monitoring Unit (EMU) are a common, and potentially preventable adverse event contributing to morbidity for patients living with epilepsy. Accurate fall risk screening is important to identify and efficiently allocate proper safety measures to high-risk patients, especially in EMUs with limited resources. We sought to compare existing screening tools for the ability to predict falls in the EMU.

View Article and Find Full Text PDF

Heart failure (HF) is a complex syndrome that affects mortality/morbidity and acts at different levels in the patient's life, resulting in a drastic impairment in multiple aspects of daily activities (e.g. physical, mental/emotional, and social) and leading to a reduction in quality of life.

View Article and Find Full Text PDF

Background: Initiation of ventricular tachycardia (VT) by programmed electrical stimulation (PES) has an important role to allow mapping and assess ablation end points. We hypothesized that substrate mapping may alter VT inducibility by mechanical bumping of critical sites.

Methods: Subjects with left ventricular scar-related VT that was inducible by PES who were undergoing ablation were included.

View Article and Find Full Text PDF

Pregnancy after thoracic organ transplantation is feasible for select individuals but requires multidisciplinary subspecialty care. Key components for a successful pregnancy after lung or heart transplantation include preconception and contraceptive planning, thorough risk stratification, optimization of maternal comorbidities and fetal health through careful monitoring, and open communication with shared decision-making. The goal of this consensus statement is to summarize the current evidence and provide guidance surrounding preconception counseling, patient risk assessment, medical management, maternal and fetal outcomes, obstetric management, and pharmacologic considerations.

View Article and Find Full Text PDF